Anti-Monopoly

The FTC has won its lawsuit against Martin Shkreli, the pharmaceutical executive infamous for jacking up the price of the antiparasitic drug Daraprim from $13.50 to $750 overnight in 2015 and later using his ill-gotten fortune to buy an exclusive Wu-Tang Clan album for $2 million. Shkreli is the quintessential corporate ghoul, having already racked up convictions for securities fraud—which resulted in an indefinite ban from the securities industries—and failure to pay $1.26 million in New York state taxes. Now, his price gouging has finally caught up with him, as the FTC successfully argued that he spearheaded an anti-competitive scheme to monopolize the drug. The presiding judge found Shkreli’s conduct to be “egregious, deliberate, repetitive, long-running, and ultimately dangerous,” issuing a $64.6 million fine and imposing a lifetime ban from the pharmaceutical industry. 

Accounting’s technical jargon makes the industry obscure to most Americans. It’s likely your next-door neighbor has no idea of the PCAOB’s activities, its responsibility to protect investors, or its history of negligence. That’s expected, but chair Williams is now working to turn the ship around to fix the shortcomings of one of America’s most consequential oligopolies, and it will improve the economic lives of an unaware public.

The RealPage scandal gives Biden a real opportunity to rally working-class support for his reelection campaign.

While former FTC commissioner Noah Phillips defends private equity from antitrust lawsuits, the media attacks current Chair Lina Khan for … doing her job.

As negotiations to prevent a government shutdown heat up once again, Democratic and Republican Representatives in the House are poised to make a play on agency resources.

A company under federal antitrust investigation for helping landlords jack up rents is not a reliable or independent source.

Two weeks ago, Federal Trade Commission (FTC) Chair Lina Khan entered a House Judiciary  Committee hearing with a target on her back. In the leadup to the hearing, Republicans readied their trumped-up attacks against Khan and the agency she leads: a barely relevant memo from a conflicted ethics officer, a list of unfounded grievances from bitter former Commissioner Christine Wilson, and absurd defenses of Elon Musk’s lazy privacy practices at Twitter. But Khan emerged unscathed, and by the end, the Republicans had lost all their fire.

Rep Jim Jordan and company had already been eyeing Khan for an investigation because she had the audacity to enforce a consent decree that Twitter violated under Elon Musk’s leadership. Then, they eagerly seized on last month’s (conveniently timed) reporting from Bloomberg which published a previously unseen memo from an FTC ethics official and accused Chair Khan of ignoring the official’s recommendation. With that backdrop, the Republicans seemed poised to strike while the iron was hot, a culmination of their years-long project to undermine Khan’s leadership and reputation. The result was … much different. Thanks to some sleuthing on our part and the bipartisan support for taking on tech monopolies, yesterday’s hearing was less a damning inquisition and more a victory lap for Khan’s rejuvenation of the FTC.

It turns out that radical ideology IS allowed at the FTC.